Results 131 to 140 of about 72,150 (302)

Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance

eJHaem
Background Despite recent advances, optimal therapeutic approaches applicable to subpopulations with primary central nervous system (CNS) lymphoma outside of clinical trials remain to be determined.
Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Li Mei Poon, Erin Paul, Matthew Ku, Mark Wong, Sylvia Ai, Ashley Beekman, Pietro R. Di Ciaccio, Michael Krigstein, Joel Wight, Caitlin Coombes, Michael Gilbertson, Amanda Tey, Jake Shortt, Chandramouli Nagarajan, Dipti Talaulikar, Nada Hamad, Sumita Ratnasingam, Shir‐Jing Ho, Tara Cochrane, Eliza A. Hawkes, Chan Y. Cheah, Stephen Opat, Gareth P. Gregory   +26 more
doaj   +1 more source

Acute lymphoblastic B‐cell leukemia or CAR‐T cell related skin changes – a relevant diagnostic challenge

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Farzan Solimani, Amrei Dilling, Konrad Heisterkamp, Frederik Damm, Olaf Penack, Christian Oberender, Philipp Le‐Coutre, Martina Rudelius, Kamran Ghoreschi, Alexander Nast   +9 more
wiley   +1 more source

Immunophenotypically Defined Mixed‐Phenotype Acute Leukemias: A Clinicopathologic Analysis of 52 Cases

eJHaem, Volume 7, Issue 1, February 2026.
Abstract Background Immunophenotypically defined mixed‐phenotype acute leukemias (MPAL) are rare and remain a diagnostic and therapeutic dilemma. We aim to explore the clinicopathologic characteristics and oncological outcomes of these entities. Methods A total of 52 patients with immunophenotypically defined MPAL were identified from our pathology ...
Bo Zhang, Olga K Weinberg, Weina Chen, Franklin Fuda, Mingyi Chen, Sharon K. Germans   +5 more
wiley   +1 more source

The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada [PDF]

, 2021
Yannan Hu, Majed Charaan, I. van Oostrum, Bart Heeg, Timothy Bell   +4 more
openalex   +1 more source

Effectiveness of the Initial Escalation of Immunochemotherapy in Patients with High Risk MALT-Lymphoma: Pilot Study Results

Клиническая онкогематология
Background. MALT-lymphoma is usually characterized with an indolent course. The factors underlying the effectiveness of the standard chemotherapy in patients with MALT-lymphomas include MALT-IPI risk group and a high SUVmax according to the results of ...
Anna Konstantinovna Smol’yaninova, N. G. Gabeeva, S. A. Tatarnikova, A. V. Belyaeva, A. M. Kovrigina, E. G. Gemdzhyan, E. E. Zvonkov   +6 more
doaj   +1 more source

Clonal Evolution and Lineage Switch from T‐Cell Acute Lymphoblastic Leukemia to Acute Myeloid Leukemia in Therapy‐Resistant PICALM::MLLT10 Leukemia

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background PICALM::MLLT10‐positive T‐ALL is rare and associated with poor prognosis. Lineage switch to AML is exceptionally uncommon, particularly after long‐term remission. Case Presentation We report an adolescent PICALM::MLLT10‐positive T‐ALL with a cortical thymocyte, non‐ETP phenotype.
Machiko Kawamura, Daichi Sadato, Masayuki Haruta, Nobuko Kubota, Yuka Harada, Takeshi Kobayashi, Noriko Doki, Fumio Kasai, Yu Nishimura, Hirofumi Kobayashi, Nobuo Maseki   +10 more
wiley   +1 more source

Cisplatin/Cytarabine/Dacarbazine/Hydroxyurea/Lomustine/Methylprednisolone/Procarbazine/Vincristine Regimen [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC‐AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN). Case Presentation Herein, we present a case of pDC‐AML in which bone marrow findings were best classified as AML, whereas ...
Benjamin J. Lee, Shawn P. Griffin, Deepa Jeyakumar, Ashley Gamayo, Sherif A. Rezk, Kiran Naqvi   +5 more
wiley   +1 more source

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia [PDF]

, 2023
Richard F. Schlenk, Daniela Weber, Julia Krzykalla, Thomas Kindler, Gerald Wulf, Bernd Hertenstein, Helmut R. Salih, T Südhoff, J Krauter, Uwe M. Martens, Swen Weßendorf, Volker Runde, Hans‐Joachim Tischler, Martin Bentz, Elisabeth Koller, Michael Heuser, Felicitas Thol, Axel Benner, Arnold Ganser, Konstanze Döhner, Hartmut Döhner   +20 more
openalex   +1 more source

Iron overload mediates cytarabine resistance in AML by inhibiting the TP53 signaling pathway

Acta Biochimica et Biophysica Sinica
Currently, chemotherapy remains the primary treatment for acute myeloid leukemia (AML). Drug resistance in AML cells is a critical factor contributing to the failure of chemotherapy remission and subsequent relapse.
Jia Yan, Li Ling, Li Ying, Zhu Xunxun, Wang Haiyan, Xu Bin, Li Qiuping, Zhang Hao   +7 more
doaj   +1 more source